• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

3.390 +0.130 (+3.99%)
Delayed Quote Updated: 4:00 PM EDT, Oct 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prelude Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
March 10, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference
March 05, 2025
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
February 11, 2025
 
Via Benzinga
News headline image
Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
February 11, 2025
 
Via Benzinga
News headline image
Morgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To Know ↗
December 19, 2023
 
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's after-hours session. ↗
February 10, 2025
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
December 11, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
November 27, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 06, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
October 24, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
October 09, 2024
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST) 
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
September 13, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
September 09, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday ↗
August 14, 2024
 
Via Benzinga
News headline image
PRLD Stock Earnings: Prelude Therapeutics Misses EPS for Q2 2024 ↗
August 12, 2024
PRLD stock results show that Prelude Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
July 09, 2024
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22 ↗
June 22, 2024
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024. 
Via Talk Markets
News headline image
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
June 03, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
May 09, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
PRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024 ↗
May 07, 2024
PRLD stock results show that Prelude Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
April 09, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
March 05, 2024
Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitor 
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
February 29, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
February 16, 2024
 
Via Benzinga
News headline image
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
February 15, 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
AI Meets Biotech: 3 Top Stocks Transforming Medical Science ↗
December 16, 2023
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Prelude Therapeutics Announces $25 Million Private Placement
December 11, 2023
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
November 01, 2023
From Prelude Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap